DiaMedica Sees Cash and Equivalents Funding Operations Through 2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy DMAC?
DiaMedica sees cash, equivalents funding operations through 2027
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DMAC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DMAC
Wall Street analysts forecast DMAC stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.320
Low
12.00
Averages
17.00
High
25.00
Current: 6.320
Low
12.00
Averages
17.00
High
25.00
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DiaMedica Reports Q1 2026 Financial Results and Clinical Updates
- Clinical Trial Progress: DiaMedica's DM199 is currently enrolling in the Phase 2 IST clinical trial for preeclampsia, with data expected in Q2 2026, which may provide critical dosing information for a potential multinational Phase 3 program.
- Acute Ischemic Stroke Study: The ReMEDy2 trial has surpassed 70% of the required enrollment, with an interim analysis planned for Q4 2026, which will determine the final number of participants needed to complete the study, thus impacting the overall timeline of the clinical trial.
- Financial Status Update: As of March 31, 2026, DiaMedica reported cash and short-term investments of $51.3 million, which is anticipated to support corporate operations through 2027, despite a decrease from $59.9 million at the end of 2025, indicating a stable financial position for ongoing clinical research.
- Increased R&D Spending: R&D expenses for Q1 2026 reached $8.0 million, significantly up from $5.7 million in Q1 2025, primarily driven by the ongoing ReMEDy2 trial and its global expansion, reflecting the company's strategic focus on research and development investment.
See More
DiaMedica Therapeutics Stock Shows Oversold Signal
- Oversold Signal: DiaMedica Therapeutics Inc (Ticker: DMAC) hit an RSI of 28.4 during Wednesday's trading, indicating an oversold condition that suggests the recent heavy selling may be exhausting, prompting bullish investors to seek buying opportunities.
- Price Fluctuation: DMAC shares traded as low as $6.065, with the current price at $6.19, showing a significant recovery from the 52-week low of $3.26, yet still far below the 52-week high of $10.4195, reflecting market uncertainty.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 57.1, DMAC's low RSI may attract bullish investors who see potential for a price rebound, potentially stimulating buying interest.
- Investor Sentiment: While DMAC is currently in an oversold state, investors should cautiously assess market sentiment and fundamentals to avoid making impulsive decisions in an uncertain market environment.
See More
DiaMedica Therapeutics Q4 2025 Earnings Call Insights
- Clinical Trial Progress: DiaMedica's DM199 Phase II trial for preeclampsia in South Africa shows statistically significant reductions in blood pressure and uterine artery pulsatility index, with no placental transfer, indicating its potential application in preeclampsia and related conditions.
- Strong Financial Position: As of December 31, 2025, the company reported $59.9 million in cash and short-term investments, which is expected to fund clinical studies and corporate operations through the end of 2027, reflecting robust financial health.
- Trial Expansion Plans: The company anticipates completing the preeclampsia expansion cohort with 12 additional patients in the first half of 2026, while also planning to initiate two new cohorts in Q2, demonstrating ongoing commitment to clinical research.
- Stroke Program Progress: DiaMedica has achieved nearly 70% enrollment of the required 200 participants for its stroke program, with guidance to complete the interim analysis by the second half of 2026, showcasing the company's execution capability and confidence in this area.
See More
DiaMedica Therapeutics Reports FY Losses
- Disappointing Earnings: DiaMedica Therapeutics reported a FY GAAP EPS of -$0.70, missing expectations by $0.02, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Cash Position Improvement: As of December 31, 2025, the company had $59.9 million in cash and short-term investments, up from $44.1 million a year earlier, suggesting improved cash management, though ongoing losses remain a concern.
- Increased Operating Cash Usage: The net cash used in operating activities for the year ended December 31, 2025, was $29.1 million, an increase from $22.1 million in 2024, reflecting heightened pressure on operational expenditures that may affect future liquidity.
- Historical Financial Insights: Historical financial data for DiaMedica Therapeutics indicates that while cash reserves have increased, persistent losses and high operational costs could limit future growth potential.
See More
Multiple Companies Set to Report Earnings
- Progress Software Earnings Outlook: Progress Software Corporation (PRGS) is expected to report earnings per share of $1.18, reflecting a 10.28% increase year-over-year, indicating the company's consistent ability to exceed market expectations, which may further boost investor confidence.
- Phreesia Earnings Surge: Phreesia, Inc. (PHR) forecasts earnings per share of $0.09, representing a staggering 181.82% increase compared to the same quarter last year, highlighting the company's strong performance in the medical information systems sector, potentially attracting more investor interest.
- Virgin Galactic Earnings Forecast: Virgin Galactic Holdings, Inc. (SPCE) anticipates earnings per share of -$1.12, although still negative, this marks a 55.73% improvement year-over-year, suggesting recovery potential in the aerospace sector, which may influence market perceptions of its future growth.
- HireQuest Earnings Decline: HireQuest, Inc. (HQI) expects earnings per share of $0.12, down 36.84% from the same quarter last year, reflecting challenges faced in the staffing industry, which could negatively impact its stock price.
See More
DiaMedica to Release Q4 Earnings on March 30
- Earnings Release Date: DiaMedica Therapeutics is set to release its Q4 earnings on March 30, with significant market attention expected, which may impact the company's stock price.
- Analyst Expectations: Analysts anticipate a quarterly loss of 18 cents per share, raising concerns about the company's profitability and potentially affecting investor confidence in the stock.
- Stock Price Movement: Ahead of the earnings report, DiaMedica's stock fell 0.9% on Friday, indicating a cautious market sentiment regarding the upcoming financial results, which may lead to short-term investor volatility.
- Market Reaction: Given the potential for the earnings report to fall short of market expectations, investors should closely monitor the results to assess the company's future financial health and its implications for stock performance.
See More
DiaMedica Reports Q1 2026 Financial Results and Clinical Updates
- Clinical Trial Progress: DiaMedica's DM199 is currently enrolling in the Phase 2 IST clinical trial for preeclampsia, with data expected in Q2 2026, which may provide critical dosing information for a potential multinational Phase 3 program.
- Acute Ischemic Stroke Study: The ReMEDy2 trial has surpassed 70% of the required enrollment, with an interim analysis planned for Q4 2026, which will determine the final number of participants needed to complete the study, thus impacting the overall timeline of the clinical trial.
- Financial Status Update: As of March 31, 2026, DiaMedica reported cash and short-term investments of $51.3 million, which is anticipated to support corporate operations through 2027, despite a decrease from $59.9 million at the end of 2025, indicating a stable financial position for ongoing clinical research.
- Increased R&D Spending: R&D expenses for Q1 2026 reached $8.0 million, significantly up from $5.7 million in Q1 2025, primarily driven by the ongoing ReMEDy2 trial and its global expansion, reflecting the company's strategic focus on research and development investment.
See More
DiaMedica Therapeutics Stock Shows Oversold Signal
- Oversold Signal: DiaMedica Therapeutics Inc (Ticker: DMAC) hit an RSI of 28.4 during Wednesday's trading, indicating an oversold condition that suggests the recent heavy selling may be exhausting, prompting bullish investors to seek buying opportunities.
- Price Fluctuation: DMAC shares traded as low as $6.065, with the current price at $6.19, showing a significant recovery from the 52-week low of $3.26, yet still far below the 52-week high of $10.4195, reflecting market uncertainty.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 57.1, DMAC's low RSI may attract bullish investors who see potential for a price rebound, potentially stimulating buying interest.
- Investor Sentiment: While DMAC is currently in an oversold state, investors should cautiously assess market sentiment and fundamentals to avoid making impulsive decisions in an uncertain market environment.
See More
DiaMedica Therapeutics Q4 2025 Earnings Call Insights
- Clinical Trial Progress: DiaMedica's DM199 Phase II trial for preeclampsia in South Africa shows statistically significant reductions in blood pressure and uterine artery pulsatility index, with no placental transfer, indicating its potential application in preeclampsia and related conditions.
- Strong Financial Position: As of December 31, 2025, the company reported $59.9 million in cash and short-term investments, which is expected to fund clinical studies and corporate operations through the end of 2027, reflecting robust financial health.
- Trial Expansion Plans: The company anticipates completing the preeclampsia expansion cohort with 12 additional patients in the first half of 2026, while also planning to initiate two new cohorts in Q2, demonstrating ongoing commitment to clinical research.
- Stroke Program Progress: DiaMedica has achieved nearly 70% enrollment of the required 200 participants for its stroke program, with guidance to complete the interim analysis by the second half of 2026, showcasing the company's execution capability and confidence in this area.
See More
DiaMedica Therapeutics Reports FY Losses
- Disappointing Earnings: DiaMedica Therapeutics reported a FY GAAP EPS of -$0.70, missing expectations by $0.02, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Cash Position Improvement: As of December 31, 2025, the company had $59.9 million in cash and short-term investments, up from $44.1 million a year earlier, suggesting improved cash management, though ongoing losses remain a concern.
- Increased Operating Cash Usage: The net cash used in operating activities for the year ended December 31, 2025, was $29.1 million, an increase from $22.1 million in 2024, reflecting heightened pressure on operational expenditures that may affect future liquidity.
- Historical Financial Insights: Historical financial data for DiaMedica Therapeutics indicates that while cash reserves have increased, persistent losses and high operational costs could limit future growth potential.
See More
Multiple Companies Set to Report Earnings
- Progress Software Earnings Outlook: Progress Software Corporation (PRGS) is expected to report earnings per share of $1.18, reflecting a 10.28% increase year-over-year, indicating the company's consistent ability to exceed market expectations, which may further boost investor confidence.
- Phreesia Earnings Surge: Phreesia, Inc. (PHR) forecasts earnings per share of $0.09, representing a staggering 181.82% increase compared to the same quarter last year, highlighting the company's strong performance in the medical information systems sector, potentially attracting more investor interest.
- Virgin Galactic Earnings Forecast: Virgin Galactic Holdings, Inc. (SPCE) anticipates earnings per share of -$1.12, although still negative, this marks a 55.73% improvement year-over-year, suggesting recovery potential in the aerospace sector, which may influence market perceptions of its future growth.
- HireQuest Earnings Decline: HireQuest, Inc. (HQI) expects earnings per share of $0.12, down 36.84% from the same quarter last year, reflecting challenges faced in the staffing industry, which could negatively impact its stock price.
See More
DiaMedica to Release Q4 Earnings on March 30
- Earnings Release Date: DiaMedica Therapeutics is set to release its Q4 earnings on March 30, with significant market attention expected, which may impact the company's stock price.
- Analyst Expectations: Analysts anticipate a quarterly loss of 18 cents per share, raising concerns about the company's profitability and potentially affecting investor confidence in the stock.
- Stock Price Movement: Ahead of the earnings report, DiaMedica's stock fell 0.9% on Friday, indicating a cautious market sentiment regarding the upcoming financial results, which may lead to short-term investor volatility.
- Market Reaction: Given the potential for the earnings report to fall short of market expectations, investors should closely monitor the results to assess the company's future financial health and its implications for stock performance.
See More
